Effect of treatment with lercanidipine on heart of Cohen-Rosenthal diabetic hypertensive rats

Hypertension

Volumn 41, Issue 6, 2003, Pages 1330-1335

  Amenta, Francesco ^a,c   Peleg, Edna ^b   Tomassoni, Daniele ^a   Sabbatini, Maurizio ^a   Rosenthal, Talma ^b  

^a UNIVERSITY OF CAMERINO   (Italy)

^b SHEBA MEDICAL CENTER   (Israel)

^c Dipto Sci Farmacologiche Med S   (Italy)

Author keywords

Blood pressure; Calcium antagonists; Coronary artery disease; Diabetes mellitus; Heart; Hypertension, genetic

Indexed keywords

LERCANIDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIABETIC HYPERTENSION; DRUG EFFECT; HEART DISEASE; MICROANGIOPATHY; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; RAT; RISK BENEFIT ANALYSIS; SPONTANEOUSLY HYPERTENSIVE RAT; STRAIN DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TUNICA MEDIA; VASCULAR RESISTANCE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY WEIGHT; CALCIUM CHANNEL BLOCKERS; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DIHYDROPYRIDINES; HEART; HYPERTENSION; MALE; MYOCARDIUM; ORGAN SIZE; RATS; RATS, INBRED SHR; RATS, INBRED STRAINS; RATS, INBRED WKY;

EID: 0037781046     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000070116.11304.23     Document Type: Article

References (41)

1. Tuck ML, Stern N. Diabetes and hypertension. J Cardiovasc Pharmacol. 1992;19:S8-S18.
2. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19:403-418.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes. other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
4. Galvan AQ, Haffner SM, Ferrannini E. Diabetes and hypertension: the scope of the problem. Blood Press. 1996;5:7-9.
5. Sower JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. Hypertension. 2001;32:1053-1059.
6. Jaffe AS. Cardiovascular effects of diabetes. Curr Opinion Cardiol. 1989;4:711-720.
7. Rosenthal T, Frohlich ED. Cardiac implications of hypertension and diabetes. Curr Opin Cardiol. 1993;8:746-756.
8. Leaners M. Cardiac complication of type 2 diabetes. Rev Med Brux. 2000;21:149-156.
9. Filtz G, Martin R, Dettmer D, Hermsdorf V, Drews H, Welt K. Protective effects of Gingko biloba extract Egb 761 on myocardium of experimentally diabetic rats. I. Ultrastructural and biochemical investigation on cardiomyocytes. Exp Toxicol Pathol. 1999;51:189-198.
10. Li C. Morphometric analysis of myocardial cells in experimental diabetic rats. Chung Hua Ping Li Hsueh Tsa Chin. 1990;19:271-274.
11. 2+ overload. Diabetes Res Clin Pract. 1996;31:S105-S112.
12. Hsiao YC, Suzuki K, Abe H, Toyota T. Ultrastructural alterations in cardiac muscle of diabetic BB Wistar rats. Virchows Arch A Pathol Anat Histopathol. 1987;411:45-52.
13. Factor SM, Minase T, Bhan R, Wolinsky H, Sonnenblink EH. Hypertensive diabetic cardiomyopathy in the rat: ultrastructural features. Virchows Arch A Pathol Anat Histopathol. 1983;398:305-317.
14. Cohen AM, Rosenmann E, Rosenthal T. The Cohen diabetic (non-insulin-dependent) hypertensive rat model: description of the model and pathologic findings. Am J Hypertens. 1993;6:989-995.
15. Santoro D, Natali A, Palombo C, Brandi LS, Piatti M, Ghione S, Ferrannini E. Effect of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension. 1992;20:181-191.
16. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension. 1994;23:145-158.
17. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Golhaber A, Palatini P, Sarti C, Fagard R. Effects of calcium channel blockade in patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:667-684.
18. Rosenthal T, Erlich Y, Rosenmann E, Cohen A. Effects of enalapril, losartan and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat. Hypertension. 1997;29:1260-1264.
19. Wiedmann P, Boehlen LM, de Courter M. Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am Heart J. 1993;125:1498-1513.
20. Giordano M, Sanders LR, Castellino P, Canessa ML, De Fronzo RA. Effect of alpha-adrenergic blockers, ACE inhibitors and calcium channel antagonist on renal function in hypertensive non-insulin-dependent diabetic patients. Nephron. 1996;72:447-453.
21. Testa R, Leonardi A, Tajana A, Riscassi E, Magliocca R, Sartani A. Lercanidipine (REC 15/2375): a novel 1.4 dihydropyridine calcium antagonist for hypertension. Cardiovasc Drugs Res. 1997;15:187-219.
22. Sironi G, Colombo D, Greto L, Testa R, Leonardi A. Antihypertensive activity of lercanidipine and its enantiomers in animal models. J Cardiovasc Pharmacol. 1997;29:S33-S40.
23. Circo A. Active dose findings for lercanidipine in a double-blind, placebo-controlled design in patients with mild to moderate hypertension. J Cardiovasc Pharmacol. 1997;29:S21-S40.
24. Mulvany MJ. Determinants of vascular characteristics haemodynamic. Hypertension. 1984;6:13-25.
25. Nicoletti A, Heudes D, Hinglais N, Appay MD, Philippe M, Sassy-Prigent C, Bariety J, Michel JB. Left ventricular fibrosis in renovascular hypertensive rats. Hypertension. 1995;26:101-111.
26. Heagerty AM, Christian A, Stuart JB, Niels K, Mulvany MJ. Small artery structure in hypertension: dual process of remodeling and growth. Hypertension. 1993;21:391-397.
27. Dwyer EM, Asif M, Ippolito T, Gillespie M. Role of hypertension, diabetes, obesity and race in the development of symptomatic myocardial dysfunction in a predominantly minority population with normal coronary arteries. Am Heart J. 2000;139:297-304.
28. Giles TD, Sander GE. Myocardial disease in hypertensive diabetic patients. Am J Med. 1989:87:23-28.
29. Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med. 1997;126:296-306.
30. Feener EP, George L King. Vascular dysfunction in diabetes mellitus. Lancet. 1997;350(suppl 1):9-13.
31. Van Hoevean KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic and hypertensive diabetic heart disease. Circulation. 1990;82:848-855.
32. Jarrett RJ, McCartney P, Keen H. The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaeridemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia. 1982;22:79-91.
33. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease and stroke mortality by degree of glycemic: the Whitehall study. Br Med J. 1983;287:867-870.
34. Wilson PW. Established risk factors and coronary artery disease: the Framingham study. Am J Hypertens. 1994;7:7-12.
35. Fein FS. Diabetic cardiomyopathy. Diabetes Care. 1990;13(suppl 4):1169-1179.
36. Campbell SE, Turek Z, Rakusan K, Kazda S. Cardiac structural remodeling after treatment of spontaneously hypertensive rats with nifedipine or nisoldipine. Cardiovasc Res. 1993;27:1350-1358.
37. Suzuki M, Yamanaka K, Nabata H, Tachibana M. Long term effects of amlodipine on organ damage, stroke and life span in stroke prone spontaneously hypertensive rats. Eur J Pharmacol. 1993;228:269-274.
38. Yamazaki T, Komuro I, Zou Y, Kudoh S, Shiojima I, Mizuno T, Hiroi Y, Nagai R, Yazaki Y. Efficient inhibition of the development of cardiac remodeling by a long-acting calcium antagonist amlodipine. Hypertension. 1998;31:32-38.
39. Susic D, Varagic J, Frohlich ED. Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats. J Hypertens. 1999;17:1209-1215.
40. Brilla CG. Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovasc Res. 2000;46:324-331.
41. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, Walker JF, Hahn RT, Dahlof B. Effects of once-daily angiotensinconverting enzyme inhibition and calcium channel blockade-based anti-hypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation. 2001;104:1248-1254.